Edwards Lifesciences raises FY23 adj. EPS view to 2.50-$2.60 from 2.48-$2.60

FY23 consensus $2.55. Raises FY23 revenue view to $5.9B-$6.1B from prior guidance of the high end of $5.6B-$6B, consensus $5.96B. “The exciting developments during the first half of the year reinforce our confidence in our patient-focused innovation strategy and our longer-term outlook, and we anticipate a year of value creation as we pursue important therapies that will benefit many more patients. We look forward to launching a number of differentiated technologies, as well as achieving important milestones across all of our product lines,” said Zovighian.